Cell Adhesion Molecules in Cardiovascular Disease and Its Risk Factors—What Can Soluble Levels Tell Us?

Andrew D. Blann and Gregory Y. H. Lip

Haemostasis, Thrombosis and Vascular Biology Unit University Department of Medicine City Hospital Birmingham B18 7QH, United Kingdom

Address correspondence and requests for reprints to: Gregory Y. H. Lip, University Department of Medicine, City Hospital, Haemostasis, Thrombosis and Vascular Biology, Dudley Road, Birmingham B18 7QH, United Kingdom.


    Introduction
 Top
 Introduction
 References
 
There are at least three reasons why considerable research energy is currently being directed toward the study of cell adhesion molecules. The blockade of the interaction between leukocytes and the endothelium by agents that mimic or inhibit these adhesion molecules may become a new class of therapeutic agents (1, 2, 3), study of the expression of the molecules on the surface of various cells or of the soluble form in the plasma may provide insights into their role(s) in pathophysiology (4, 5), and levels of soluble cell adhesion molecules in the plasma may be useful tools in stratifying disease severity or prognosis (6, 7).

However, these aspects may be inter-related because soluble forms of these adhesion molecules themselves may potentially interfere with leukocyte/endothelial cell interactions, at least in vitro (8, 9). Despite this, soluble adhesion molecules may still be useful in dissecting the pathophysiological events in cardiovascular disease, as it may be presumed that changes in levels may relate to activation or damage to various cells, such as the platelet and endothelium.

The selectin family of adhesion molecules has three members. Soluble P-selectin is believed to be the product of activated platelets, although the endothelium displays a membrane-bound form (10, 11). Increased levels are found in a number of conditions, including thrombotic disorders, diabetes, and ischaemic heart disease, and in the latter, raised levels predicted adverse events (12, 13, 14). Although increased levels of soluble E-selectin are the result of cytokine activation of endothelial cells in vitro (15), and raised levels in the plasma have been reported in variant (but not stable) angina (16) and in ischaemic heart disease (17), such raised levels do not seem to predict adverse events cardiovascular events (18) but do predict progression of peripheral atherosclerosis (19). It is still unclear whether or not levels of soluble L-selectin, derived from leukocytes, are altered in cardiovascular diseases although we have been unable to find differences between patients with peripheral atherosclerosis and healthy controls (20). However, Siminiak et al. (21) recently reported raised levels within 1 h to 3 days following admission for acute myocardial infarction, and Haught et al. (22) found low levels in stable and unstable angina, and in acute myocardial infarction.

The second major group of adhesion molecules belongs to the immunoglobulin supergene family, and three of its members warrant attention. Soluble intercellular adhesion molecule-1 (sICAM-1) is a likely product of many cells, including the endothelium and leukocytes. Also influenced by inflammatory cytokines in vitro (15), raised levels are found in many conditions, including angina (16) and both coronary artery disease and peripheral artery disease (23). However, although raised levels in healthy men predict adverse events (6), the association is weak when there is a background of existing atherosclerosis (7). Conversely, vascular cell adhesion molecule-1 (sVCAM-1) does not seem to be increased in the plasma of patients with angina or coronary artery disease (16, 23): neither do levels predict adverse outcome (7). However, levels do rise slowly (reaching a peak on day 3) after an acute myocardial infarction and are moderately raised in some forms of peripheral atherosclerosis, where levels correlated with the extent of disease (24, 25). Soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1) may arise from many cells, including endothelial cells, platelets, and leukocytes. Nevertheless, we have been unable to find differences in the plasma of patients with coronary artery disease or peripheral artery disease compared with controls (26).

It has long been proposed that damage to the endothelium is important in the development and/or progression of atherosclerosis (27), and increased levels of endothelial cell markers in the plasma of subjects who go onto suffer adverse cardiovascular events support this concept (28, 29). Among the most commonly used endothelial cell markers are von Willebrand factor, soluble thrombomodulin, and soluble E-selectin (17, 18, 19). Increased levels of sICAM and sVCAM are often taken to imply damage and/or stimulation of the endothelium, but the expression of these molecules on smooth muscle cells, leukocytes, and tumor cells suggests some caution may be necessary (30, 31, 32). However, despite these caveats, increased levels of all these molecules in a variety of cardiovascular, inflammatory, and neoplastic diseases are well established, and in many cases may be useful in predicting clinical outcome, but the precise mechanisms for these increased levels are often unclear.

Diabetes is a case in point. Numerous groups have shown raised levels of various markers in both type 1 and type 2 diabetes mellitus (reviewed in Refs. 33, 34), and it, therefore, follows that these changes may be related to the profound alterations in the metabolic homeostasis in the patients. Among the primary biochemical changes in diabetes are, of course, disturbances in blood glucose, insulin, and lipids, any of which may, in theory, be responsible for changes in endothelial and other markers, blood pressure control (leading to hypertension), and renal integrity (leading to albuminuria and renal failure) (35). Therefore, the pursuit of the mechanisms leading to the changes in the makers should provide additional clues to the pathophysiology of this disease. For example, despite reporting raised levels of von Willebrand factor, soluble E selectin, and VCAM in a case-control study of 70 patients with type 2 diabetes, Steiner et al. (36) were unable to relate such increases to glycated hemoglobin or fructoasmine. However, they did correlate von Willebrand factor with hypertension and soluble E-selectin with low-density lipoprotein cholesterol.

In the current issue of The Journal of Clinical Endocrinology & Metabolism, Jilma et al. (37) have taken a further step in the search for the mechanism(s) behind these changes. Perhaps surprisingly, the continued infusion of insulin into healthy young men over a 24-h period resulted in no changes in sICAM, sVCAM, soluble E-selectin, von Willebrand factor or soluble thrombomodulin. Indeed, this is contrary to previous reports that insulin directly increases circulating adhesion molecules in diabetics and that high insulin levels do not induce endothelial function. However, although, in our view, correctly interpreting the study by Jilma et al. (37) as showing no short-term effect of insulin on the endothelium, it begs the question of whether or not this effect is present in patients with either form of diabetes and, if so, whether such an effect occurs over a longer period than that studied in this paper. Perhaps it is the degree of insulin resistance and ethnicity that may be the more important factors. For example, Chen et al. (38) studied the relationship between insulin resistance, soluble adhesion molecules E-selectin, sICAM, and sVCAM, and lipoprotein concentrations in 28 healthy, nondiabetic, and normotensive individuals and found that the degree of insulin resistance was significantly correlated with concentrations of the measured adhesion molecules, even after adjustment for differences in age, gender, body mass index, and all measures of lipoprotein concentrations. Thus, the relationships between soluble adhesion molecules in patients with hypertension, type 2 diabetes, and dyslipidemia may be due to the presence of insulin resistance in these clinical syndromes and raises the possibility that that insulin resistance may predispose individuals to coronary heart disease by activation of cellular adhesion molecules. Perhaps the latter may be one mechanism for the increase in coronary heart disease among the Indo-Asian population (and other ethnic groups, such as Pima Indians), who have a particularly high prevalence of insulin resistance (39).

When these questions are answered, we shall perhaps have a better understanding on the relationships between the metabolic changes in diabetes and their influence on the endothelium and whether or not this represents an additional therapeutic direction.


    Acknowledgments
 
We acknowledge the support of the City Hospital NHS Trust Research and Development Programme for support of the Haemostasis, Thrombosis and Vascular Biology Unit.

Received February 2, 2000.

Accepted February 5, 2000.


    References
 Top
 Introduction
 References
 

  1. Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM. 1999 Recombinant soluble P-selectin ligand-1 protects against myocardial ischemic reperfusion in cats. Cardiovasc Res. 41:65–76.[CrossRef][Medline]
  2. Zhang RL, Chopp M, Jiang N, et al. 1995 Anti-intercellular adhesion molecule-1 antibody reduces ischaemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke. 26:1438–1443.[Abstract/Free Full Text]
  3. Tsukamoto K, Yokono K, Amano K, et al. 1995 Administration of monoclonal antibodies against vascular cell adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice. Cell Immunol. 165:193–201.[CrossRef][Medline]
  4. Tanio JW, Chandrasekar BB, Albelda SM, Eisen HJ. 1994 Differential expression of the cell adhesion molecules ICAM-1, VCAM-1 and E-selectin in normal and post-transplantation myocardium. Circulation. 89:1760–1768.[Abstract]
  5. Kuzu I, Bicknell R, Fletcher CDM, Gatter KC. 1993 Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumours. Lab Invest. 69:322–328.[Medline]
  6. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. 1998 Plasma concentrations of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet. 351:88–92.[CrossRef][Medline]
  7. Blann AD, Seigneur M, Steiner M, Miller JP, McCollum CN. 1998 Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolaemia: relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events. Thromb Haemost. 79:1080–1085.[Medline]
  8. Schleiffenbaum B, Spertinin O, Tedder TF. 1992 Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol. 11:229–238.
  9. Gamble JR, Skinner MP, Berndt MC, Vadas MA. 1990 Prevention of activated neutrophil adhesion to endothelium by soluble adhesion protein GMP 140. Science. 249:414–417.[Medline]
  10. Fijnheer R, Frijns CJM, Korteweg J, et al. 1997 The origin of P-selectin as a circulating plasma protein. Thromb Haemost. 77:1081–1085.[Medline]
  11. Blann AD, Lip GYH. 1997 Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 128:135–138.[CrossRef][Medline]
  12. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. 1994 Plasma P-selectin is increased in thrombotic consumptive disorders. Blood. 83:1535–1541.[Abstract/Free Full Text]
  13. Jilma B, Fasching P, Ruthner C, et al. 1996 Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost. 76:328–332.[Medline]
  14. Blann AD, Faragher EB, McCollum CN. 1997 Increased soluble P-selectin in ischaemic heart disease: a new marker for the progression of atherosclerosis. Blood Coag Fibrinolysis. 8:383–390.[Medline]
  15. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. 1992 Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 187:584–589.[Medline]
  16. Miwa K, Igawa A, Inoue H. 1997 Soluble E-selectin, ICAM-1 and VCAM-1 in systemic and coronary circulation in patients with variant angina. Cardiovasc Res. 36:37–44.[CrossRef][Medline]
  17. Blann AD, Amiral J, McCollum CN. 1996 Soluble endothelial cell markers and adhesion molecules in ischaemic heart disease. Br J Haematol. 95:263–265.[Medline]
  18. Blann AD, Amiral J, McCollum CN. 1997 Increased soluble thrombomodulin and soluble E-selectin as predictors of disease following myocardial infarction. Eur J Haematol. 58:115–120.
  19. Belch JJF, Shaw JW, Kirk G, et al. 1997 The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing precutaneous transluminal angioplasty. Circulation. 95:2027–2031.[Abstract/Free Full Text]
  20. Blann AD, Morris J, McCollum CN. 1996 Soluble L-selectin in atherosclerosis: relationship to soluble E-selectin and soluble P-selectin. Atherosclerosis. 126:227–231.[CrossRef][Medline]
  21. Siminiak T, Smielecki J, Dye JF, et al. 1996 Detection of soluble adhesion molecules VCAM-1 and L-selectin during myocardial infarction. Eur Heart J. 17 (Abstract Supplement):353.
  22. Haught WH, Mansour M, Rothlein R, et al. 1996 Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischaemic heart disease. Am Heart J. 132:1–8.[Medline]
  23. Blann AD, McCollum CN. 1994 Increased levels of soluble adhesion molecules in atherosclerosis. Thromb Haemost. 72:151–154.[Medline]
  24. Peter K, Nawroth P, Conradt C, et al. 1997 Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating ICAM-1, E-selectin, P-selectin and thrombomodulin. Arterioscler Thromb Vasc Biol. 17:505–512.[Abstract/Free Full Text]
  25. De Caterina R, Basta G, Lazzerini G, et al. 1997 Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscl Thromob Vasc Biol. 17:2646–2654.[Abstract/Free Full Text]
  26. Blann AD, Wadley M, Dobrotova M, Jayson MI, Sanders P, McCollum CN. 1998 Soluble PECAM in cancer, atherosclerosis and in connective tissue diseases. Blood Coag Fibrinolysis. 9:99–103.[Medline]
  27. Ross R. 1993 The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809.
  28. Blann AD. 1999 Endothelial cell damage and the development or progression of atherosclerosis. Clin Sci97 :119–121.
  29. Thompson SG, Kienast J, Pyke SDM, et al. for the ECAT Group. 1995 Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332;635–641.
  30. Braun M, Pietsch P, Schror K, Baumann G, Felix SB. 1999 Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc Res. 41:395–341.[CrossRef][Medline]
  31. Wittig BM, Treichel U, Blaheta R, et al. 1997 Soluble E-selectin enhances intercellular adhesion molecule-1 (ICAM-1) expression in human tumour cell lines. Exp Cell Res. 237:364–370.[CrossRef][Medline]
  32. Couffinhal T, Duplaa C, Labat L, et al. 1993 Tumour necrosis factor-{alpha} stimulates ICAM-1 expression in human vascular smooth muscle cells. Arterioscler Thromb. 13:407–414.[Abstract]
  33. Carter AM, Grant PJ. 1997 Vascular homeostasis, adhesions molecules, and macrovascular disease in non-insulin dependent diabetes mellitus. Diabetic Med. 14:423–432.[CrossRef][Medline]
  34. Blann AD, Lip GYH. 1998 Endothelial integrity, soluble adhesion molecules and platelets markers in type 1 diabetes mellitus. Diabetic Med. 15:634–642.[CrossRef][Medline]
  35. Stehouwer CDA, Lambert J, Donker AJM, van Hinsburgh VWM. 1997 Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 34:55–68.[CrossRef][Medline]
  36. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. 1994 Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic controls. Thromb Haemost. 72:979–984.[Medline]
  37. Jilma B, Dallinger S, Hergovich N, Eichler HG, Richter V, Wagner OF. 2000 Effects of hyperinsulinaemia on plasma levels of circulating adhesion molecules. J Clin Endocrinol Metab. 85:1748–1751.[Abstract/Free Full Text]
  38. Chen NG, Holmes M, Reaven GM. 1999 Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab. 84:3485–3489.[Abstract/Free Full Text]
  39. Williams B. 1995 Westernised Asians and cardiovascular disease: nature or nuture? Lancet. 345:401–402.[CrossRef][Medline]